Sirion Therapeutics, Inc. has entered into an exclusive licensing agreement with Laboratories Thea (France) for the U.S. rights to develop and market a topical ophthalmic gel containing ganciclovir for the treatment of certain viral and superficial eye infections.
Marketed by Thea in Europe under the brand name Virgan®, the ganciclovir eye gel is indicated for the treatment of ocular viral infections for over 10 years.
According to Dr. C. Stephen Foster, Founder and President of Massachusetts Eye Research and Surgery Institute (MERSI), Clinical Professor of Ophthalmology, Harvard Medical School:
Find more details from the press release (a pdf file)"Upon regulatory approval, ganciclovir gel would become the first topical ophthalmic anti-viral treatment launched in the U.S. in over two decades.
This product has the potential to advance the medical treatment of herpes simplex keratitis.
Herpes simplex keratitis remains the leading cause of corneal blindness in the United States."
Comment Preview